REFERENCES
- Panchagnula R, Agrawal S, Kaul CL. Fixed dose combinations in the treatment of tuberculosis. Ind J Pharm Sci 2001; 63: 1–9, [CSA]
- Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed dose combination tablets for treatment of tuberculosis. Bulletin of the World Health Organization 2001; 79: 61–8, [INFOTRIEVE], [CSA]
- Panchagnula R, Agrawal S, Ashokraj Y, Varma MVS, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscignio G, Wire R, Laing R, Evans P, Moore T. Fixed dose combination for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective. Meth Find Exptl Clin Pharmacol 2004; 26: 703–21, [CSA], [CROSSREF]
- Singh S, Mariappan TT, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from fixed dose combination (FDC) products and the likely solutions to the problem. Int J Pharm 2001; 228: 5–17, [INFOTRIEVE], [CSA], [CROSSREF]
- Panchagnula R, Agrawal S. Biopharmaceutics and pharmacokinetics in variable bioavailability of rifampicin. Int J Pharm 2004; 271: 1–4, [INFOTRIEVE], [CSA], [CROSSREF]
- Dressman JB. Dissolution testing of immediate release products and its application to forcasting in vivo performance. Oral drug absorption: prediction and assessment, JB Dressman, H Lennernas. Marcel Dekker, New York 2000; 185–7, 2000
- Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. Solid state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci 2004; 22: 127–44, [INFOTRIEVE], [CSA], [CROSSREF]
- Agrawal S, Panchagnula R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. Die Pharmazie 2004; 59: 775–81, [INFOTRIEVE], [CSA]
- Lotter AP, Flanagan DR, Palepu NR, Guillory JK. A simple reproducible method for determining dissolution rates of hydrophobic powders. Pharm Tech 1983; 56–66, [CSA]
- Taylor LS, Langkilde FW. Evaluation of solid-state forms present in tablets by raman spectroscopy. J Pharm Sci 2000; 89: 1342–53, [INFOTRIEVE], [CSA], [CROSSREF]
- Suryanarayanan R, Herman CS. Quantitative analysis of active ingredient in a multi-component tablet formulation by powder X-ray diffractometry. Int J Pharm 1991; 77: 287–95, [CSA], [CROSSREF]
- Cooper VB, Pearce GES, Petts CR. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction. J Pharm Pharmacol 2003; 1323–9, [CSA], [CROSSREF]
- Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech 1996; 20: 64–74, [CSA]
- USP 24/NF 19. United States Pharmacopoeial Convention, Rockville, MD 2000; 941–1943